Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Ars Pharmaceuticals Inc's Business Segments
Ars Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
6
Largest Segment
Product
Total Revenue
$ 34
Countrys Reported
2
Revenue Share by Reportable Segment - FY
- Product0%
- US0%
- Revenue under supply agreements30.1%
- Non Us20.5%
- DK17.1%
- Denmark10%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 44 | - |
| US | $ 44 | - |
| Revenue under supply agreements | $ 10 | 30.1% |
3 more segments available
Sign in to unlock the full Ars Pharmaceuticals Inc dataset.
Revenue Share by Country - FY
- US76.9%
- DK12.2%
Revenue by Geographic Country - FY
| Country | Revenue (Millions) | % of Total |
|---|---|---|
| US | $ 17 | 76.9% |
| DK | $ 3 | 12.2% |
Revenue by Product & Service Category - FY
- Product76.9%
- Revenue under supply agreements12.1%
- Revenue under collaboration agreements11%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 17 | 76.9% |
| Revenue under supply agreements | $ 3 | 12.1% |
| Revenue under collaboration agreements | $ 2 | 11% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Product0%
- US0%
- Revenue under supply agreements30.1%
- Non Us20.5%
- DK17.1%
- Denmark10%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 44 | - |
| US | $ 44 | - |
| Revenue under supply agreements | $ 10 | 30.1% |
3 more segments available
Sign in to unlock the full Ars Pharmaceuticals Inc dataset.
Description of Ars Pharmaceuticals Inc
Ars Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company that specializes in developing and commercializing novel therapies for various conditions in the areas of pulmonary and life-threatening diseases. The company was founded in 2009 and has its headquarters located in Waltham, Massachusetts.
Ars Pharmaceuticals Inc. is dedicated to developing innovative solutions that provide significant benefits to patients suffering from serious respiratory and related illnesses. Its primary focus is on developing inhaled nitric oxide (iNO) therapies, which are aimed at treating specific respiratory diseases such as pulmonary hypertension, ventilator-associated pneumonia, and acute respiratory distress syndrome (ARDS).
The company's lead product candidate, AP-002, is a Phase 2b/3 clinical stage inhaled nitric oxide product designed to improve oxygenation, decrease pulmonary artery pressure, and decrease right ventricular hypertrophy in patients with pulmonary hypertension. AP-002 has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), which highlights the significant benefits that it could provide to patients with unmet medical needs.
In addition to its work on inhaled nitric oxide therapies, Ars Pharmaceuticals Inc. is also developing other novel products for the treatment of respiratory conditions. The company's proprietary platform technology, known as Amplivant, is used to generate targeted, nontoxic peptides that bind to specific cells and inhibit harmful inflammatory pathways. Amplivant has the potential to treat inflammation-driven diseases such as cystic fibrosis, chronic obstructive pulmonary disease (COPD), and asthma.
Ars Pharmaceuticals Inc. is backed by a group of experienced investors, including OrbiMed Advisors, RA Capital Management, and Polaris Partners. The company has formed strategic partnerships with leading academic institutions, such as the University of Massachusetts Medical School and Duke University, to advance its research and development programs.
Overall, Ars Pharmaceuticals Inc. is a biopharmaceutical company with a clear focus on developing innovative therapies to address unmet medical needs in the areas of pulmonary and life-threatening diseases. Its commitment to its mission, along with its novel technologies and strategic partnerships, make it an exciting player in the biopharmaceutical industry.
Ars Pharmaceuticals Inc. is dedicated to developing innovative solutions that provide significant benefits to patients suffering from serious respiratory and related illnesses. Its primary focus is on developing inhaled nitric oxide (iNO) therapies, which are aimed at treating specific respiratory diseases such as pulmonary hypertension, ventilator-associated pneumonia, and acute respiratory distress syndrome (ARDS).
The company's lead product candidate, AP-002, is a Phase 2b/3 clinical stage inhaled nitric oxide product designed to improve oxygenation, decrease pulmonary artery pressure, and decrease right ventricular hypertrophy in patients with pulmonary hypertension. AP-002 has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), which highlights the significant benefits that it could provide to patients with unmet medical needs.
In addition to its work on inhaled nitric oxide therapies, Ars Pharmaceuticals Inc. is also developing other novel products for the treatment of respiratory conditions. The company's proprietary platform technology, known as Amplivant, is used to generate targeted, nontoxic peptides that bind to specific cells and inhibit harmful inflammatory pathways. Amplivant has the potential to treat inflammation-driven diseases such as cystic fibrosis, chronic obstructive pulmonary disease (COPD), and asthma.
Ars Pharmaceuticals Inc. is backed by a group of experienced investors, including OrbiMed Advisors, RA Capital Management, and Polaris Partners. The company has formed strategic partnerships with leading academic institutions, such as the University of Massachusetts Medical School and Duke University, to advance its research and development programs.
Overall, Ars Pharmaceuticals Inc. is a biopharmaceutical company with a clear focus on developing innovative therapies to address unmet medical needs in the areas of pulmonary and life-threatening diseases. Its commitment to its mission, along with its novel technologies and strategic partnerships, make it an exciting player in the biopharmaceutical industry.
Ars Pharmaceuticals Inc Overview
Ars Pharmaceuticals Inc is a forward-thinking pharmaceutical company dedicated to the treatment of respiratory diseases. The company is distinguished by its commitment to innovation in drug delivery systems and holistic patient support. Below is an extensive overview of its segments, products, and services.
Segments
1. Research & Development (R&D)
- The R&D segment at Ars Pharmaceuticals is pivotal to the companys mission. This team specializes in the exploration of novel compounds and formulations through preclinical and clinical research. The R&D efforts are directed toward not just developing new therapies but also optimizing existing products for better efficacy and safety. Clinical trials are conducted to ensure that new therapies meet regulatory standards and provide targeted relief for conditions such as asthma and chronic obstructive pulmonary disease (COPD). The researchers at Ars continuously monitor advancements in drug delivery technologies to stay at the forefront of respiratory care innovations.
2. Sales and Marketing
- The Sales and Marketing segment plays a crucial role in bringing Ars Pharmaceuticals products to market. This team works diligently to build relationships with healthcare providers, pharmacies, and hospitals to ensure broad access to its innovative products. They develop marketing strategies that educate healthcare professionals about the benefits and applications of the companys offerings. This segment also tracks market trends and conducts competitive analysis to adjust strategies accordingly, ensuring that the company remains relevant and responsive to the needs of the healthcare industry.
Products
1. AIRISTA
- AIRISTA is the flagship product of Ars Pharmaceuticals, regarded as a groundbreaking drug-device combination therapy. It is designed to deliver aerosolized medications directly to the lungs for patients suffering from respiratory diseases like asthma and COPD. AIRISTA utilizes advanced inhalation technology to enhance drug delivery efficiency, enabling patients to achieve better control of their conditions. This product stands out because it not only provides therapeutic benefits but also improves the overall patient experience through easier usage.
2. Other Respiratory Products
- In addition to AIRISTA, Ars Pharmaceuticals offers a comprehensive portfolio of pharmaceutical products aimed at treating respiratory diseases. This portfolio includes:
- Bronchodilators: Medications designed to relax and widen the air passages in the lungs, helping to alleviate symptoms of asthma and COPD.
- Anti-inflammatory Drugs: These medications help to reduce inflammation in the airways, providing relief from respiratory symptoms.
- Inhalers and Nebulizers: Devices designed for the effective delivery of medication to patients, ensuring that users receive the full therapeutic benefit of their prescriptions.
Services
1. Patient Education and Support
- Understanding that medication adherence and lifestyle management are crucial for patients with respiratory conditions, Ars Pharmaceuticals has developed comprehensive patient education programs. These programs provide supportive resources aimed at empowering patients through:
- Information on effective symptom management strategies.
- Guidelines for proper medication usage to maximize efficacy.
- Wellness initiatives addressing lifestyle factors that influence respiratory health.
2. Clinical Research
- The Clinical Research segment focuses on validating the safety and efficacy of Ars Pharmaceuticals products. This involves conducting rigorously designed clinical trials that are in line with FDA regulations and international standards. The research team works closely with regulatory bodies to ensure that its products not only meet safety standards but also provide meaningful clinical benefits to patients. Continuous research efforts also seek to innovate therapeutic options for future respiratory health.
3. Consulting and Education
- Ars Pharmaceuticals offers consulting and educational services aimed at healthcare professionals and institutions. This segment is committed to enhancing the understanding of respiratory diseases and their treatments through:
- Training programs for healthcare providers on the use and benefits of respiratory therapies.
- Dissemination of up-to-date research findings and treatment protocols.
- Collaborative initiatives to improve the overall quality of patient care in respiratory health.
Conclusion
Ars Pharmaceuticals Inc is dedicated to developing innovative solutions and products for the management of respiratory diseases. With a strong focus on research and development, extensive product offerings, and dedicated services aimed at patient support and healthcare education, the company’s efforts are geared towards improving the lives of individuals affected by respiratory conditions. This multifaceted approach ensures that Ars Pharmaceuticals remains a significant contributor to advancements in respiratory care.
Ars Pharmaceuticals Inc is a forward-thinking pharmaceutical company dedicated to the treatment of respiratory diseases. The company is distinguished by its commitment to innovation in drug delivery systems and holistic patient support. Below is an extensive overview of its segments, products, and services.
Segments
1. Research & Development (R&D)
- The R&D segment at Ars Pharmaceuticals is pivotal to the companys mission. This team specializes in the exploration of novel compounds and formulations through preclinical and clinical research. The R&D efforts are directed toward not just developing new therapies but also optimizing existing products for better efficacy and safety. Clinical trials are conducted to ensure that new therapies meet regulatory standards and provide targeted relief for conditions such as asthma and chronic obstructive pulmonary disease (COPD). The researchers at Ars continuously monitor advancements in drug delivery technologies to stay at the forefront of respiratory care innovations.
2. Sales and Marketing
- The Sales and Marketing segment plays a crucial role in bringing Ars Pharmaceuticals products to market. This team works diligently to build relationships with healthcare providers, pharmacies, and hospitals to ensure broad access to its innovative products. They develop marketing strategies that educate healthcare professionals about the benefits and applications of the companys offerings. This segment also tracks market trends and conducts competitive analysis to adjust strategies accordingly, ensuring that the company remains relevant and responsive to the needs of the healthcare industry.
Products
1. AIRISTA
- AIRISTA is the flagship product of Ars Pharmaceuticals, regarded as a groundbreaking drug-device combination therapy. It is designed to deliver aerosolized medications directly to the lungs for patients suffering from respiratory diseases like asthma and COPD. AIRISTA utilizes advanced inhalation technology to enhance drug delivery efficiency, enabling patients to achieve better control of their conditions. This product stands out because it not only provides therapeutic benefits but also improves the overall patient experience through easier usage.
2. Other Respiratory Products
- In addition to AIRISTA, Ars Pharmaceuticals offers a comprehensive portfolio of pharmaceutical products aimed at treating respiratory diseases. This portfolio includes:
- Bronchodilators: Medications designed to relax and widen the air passages in the lungs, helping to alleviate symptoms of asthma and COPD.
- Anti-inflammatory Drugs: These medications help to reduce inflammation in the airways, providing relief from respiratory symptoms.
- Inhalers and Nebulizers: Devices designed for the effective delivery of medication to patients, ensuring that users receive the full therapeutic benefit of their prescriptions.
Services
1. Patient Education and Support
- Understanding that medication adherence and lifestyle management are crucial for patients with respiratory conditions, Ars Pharmaceuticals has developed comprehensive patient education programs. These programs provide supportive resources aimed at empowering patients through:
- Information on effective symptom management strategies.
- Guidelines for proper medication usage to maximize efficacy.
- Wellness initiatives addressing lifestyle factors that influence respiratory health.
2. Clinical Research
- The Clinical Research segment focuses on validating the safety and efficacy of Ars Pharmaceuticals products. This involves conducting rigorously designed clinical trials that are in line with FDA regulations and international standards. The research team works closely with regulatory bodies to ensure that its products not only meet safety standards but also provide meaningful clinical benefits to patients. Continuous research efforts also seek to innovate therapeutic options for future respiratory health.
3. Consulting and Education
- Ars Pharmaceuticals offers consulting and educational services aimed at healthcare professionals and institutions. This segment is committed to enhancing the understanding of respiratory diseases and their treatments through:
- Training programs for healthcare providers on the use and benefits of respiratory therapies.
- Dissemination of up-to-date research findings and treatment protocols.
- Collaborative initiatives to improve the overall quality of patient care in respiratory health.
Conclusion
Ars Pharmaceuticals Inc is dedicated to developing innovative solutions and products for the management of respiratory diseases. With a strong focus on research and development, extensive product offerings, and dedicated services aimed at patient support and healthcare education, the company’s efforts are geared towards improving the lives of individuals affected by respiratory conditions. This multifaceted approach ensures that Ars Pharmaceuticals remains a significant contributor to advancements in respiratory care.